Samsung Bioepis Moves Swiftly To Denosumab Phase III

SB16 Biosimilar Rival To Prolia Progresses To Phase III Trials

 
• By David Wallace
  
Clinical Trial
Samsung Bioepis’ SB16 Denosumab Biosimilar Moves To Phase III • Source: Shutterstock

More from Biosimilars

More from Products